These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 402652)

  • 1. The sphiningolipidoses: an overview.
    West HH
    Postgrad Med; 1977 Mar; 61(3):90-3, 95. PubMed ID: 402652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentrations of an activator protein for sphingolipid hydrolysis in liver and brain samples from patients with lysosomal storage diseases.
    Inui K; Wenger DA
    J Clin Invest; 1983 Nov; 72(5):1622-8. PubMed ID: 6415115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy of Sphingolipid Metabolic Disorders.
    Shaimardanova AA; Solovyeva VV; Issa SS; Rizvanov AA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic findings and current developments in sphingolipidoses.
    Pilz H; Heipertz R; Seidel D
    Hum Genet; 1979 Mar; 47(2):113-34. PubMed ID: 108196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipidoses in Turkey.
    Ozkara HA; Topçu M
    Brain Dev; 2004 Sep; 26(6):363-6. PubMed ID: 15275696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses.
    Kobayashi T; Goto I; Okada S; Orii T; Ohno K; Nakano T
    J Neurochem; 1992 Oct; 59(4):1452-8. PubMed ID: 1402895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activator protein for the enzymic hydrolysis of sphingolipids and their relationships to sphingolipidosis. Special reference to the catabolism of GM2 ganglioside].
    Hirabayashi Y; Li YT; Li SC
    Seikagaku; 1983; 55(1):1-13. PubMed ID: 6405000
    [No Abstract]   [Full Text] [Related]  

  • 8. Sphingolipid metabolism in neural tissues.
    Brady RO
    Neurosci Res (N Y); 1969; 2(0):301-15. PubMed ID: 4950732
    [No Abstract]   [Full Text] [Related]  

  • 9. Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in cultured skin fibroblasts from sphingolipidosis patients.
    Fujiwaki T; Yamaguchi S; Sukegawa K; Taketomi T
    Brain Dev; 2002 Apr; 24(3):170-3. PubMed ID: 11934514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential diagnosis of congenital lipidoses by lipid analyses of body fluids, biopsy and autopsy tissue].
    Pilz H; Heipertz R
    Fortschr Neurol Psychiatr Grenzgeb; 1975 Nov; 43(11):602-17. PubMed ID: 53174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: A novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease.
    Pettazzoni M; Froissart R; Pagan C; Vanier MT; Ruet S; Latour P; Guffon N; Fouilhoux A; Germain DP; Levade T; Vianey-Saban C; Piraud M; Cheillan D
    PLoS One; 2017; 12(7):e0181700. PubMed ID: 28749998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry for analysis of sphingolipids in tissues from sphingolipidosis patients.
    Fujiwaki T; Yamaguchi S; Sukegawa K; Taketomi T
    J Chromatogr B Biomed Sci Appl; 1999 Aug; 731(1):45-52. PubMed ID: 10491988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in sphingolipidosis research].
    Tamai Y; Kojima H
    Tanpakushitsu Kakusan Koso; 1990 May; 35(7 Suppl):1291-303. PubMed ID: 1972585
    [No Abstract]   [Full Text] [Related]  

  • 14. Membrane lipids and their degradation compounds control GM2 catabolism at intralysosomal luminal vesicles.
    Anheuser S; Breiden B; Sandhoff K
    J Lipid Res; 2019 Jun; 60(6):1099-1111. PubMed ID: 30988135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease.
    Bradová V; Smíd F; Ulrich-Bott B; Roggendorf W; Paton BC; Harzer K
    Hum Genet; 1993 Sep; 92(2):143-52. PubMed ID: 8370580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited lipid storage diseases of the central nervous system.
    Percy AK; Shapiro LJ; Kaback MM
    Curr Probl Pediatr; 1979 Sep; 9(11):1-51. PubMed ID: 117977
    [No Abstract]   [Full Text] [Related]  

  • 17. [A sphingolipidosis with the accumulation of neutral glycosphingolipids, AO2(GM3) and A1(GM2)-ganglioside (author's transl)].
    Kerènyi L; Kannan R; Gielen W; Debuch H
    Z Klin Chem Klin Biochem; 1974 Nov; 12(11):487-93. PubMed ID: 4216195
    [No Abstract]   [Full Text] [Related]  

  • 18. Enzymatic abnormalities in diseases of sphingolipid metabolism.
    Brady RO
    Clin Chem; 1967 Jul; 13(7):565-77. PubMed ID: 5006481
    [No Abstract]   [Full Text] [Related]  

  • 19. From sheep to mice to cells: tools for the study of the sphingolipidoses.
    Zigdon H; Meshcheriakova A; Futerman AH
    Biochim Biophys Acta; 2014 Aug; 1841(8):1189-99. PubMed ID: 24607565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further developments in studies in sphingolipidoses: "missing enzymes".
    Brady RO
    Riv Patol Nerv Ment; 1970 Oct; 91(5):263-73. PubMed ID: 5525771
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.